Top

Journal of Endocrinological Investigation

Published in:

01-09-2016 | Original Article

Positive correlation of serum HDL cholesterol with blood mercury concentration in metabolic syndrome Korean men (analysis of KNANES 2008–2010, 2013)

Authors: S. J. Park, K. J. Yeum, B. Choi, Y. S. Kim, N. S. Joo

Published in: Journal of Endocrinological Investigation | Issue 9/2016

Abstracts

Purpose

High-density lipoprotein cholesterol (HDLC) is anti-inflammatory in the basal state and pro-inflammatory during the acute-phase response. Blood mercury also has an inflammatory property. Therefore, the aim of this study was to investigate the relationship between serum HDLC and blood mercury concentration in relation with metabolic syndrome (MS).

Methods

The data of 7616 subjects (3713 men and 3903 women), over 20 years of age, from 2008 to 2013, Korea National Health and Nutrition Examination Survey were selected for cross-sectional analyses. Correlation and regression of serum HDLC and blood mercury were initially done. We compared serum HDLC concentration according to blood mercury quartile after adjustment for relevant variables in subjects with MS.

Results

Mean blood mercury concentrations is 5.6 and 3.9 μg/dL in men and women, respectively. Blood mercury concentration in MS subjects was positively correlated with serum HDLC concentration, especially in men. In addition, HDLC concentration was significantly higher according to the higher blood mercury quartile.

Conclusion

Serum HDLC was positively associated with blood mercury concentration in MS Korean men. Therefore, elevated blood mercury may be a factor to increase serum HDLC concentration in MS men.

Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21):2709–2716CrossRefPubMed

Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National health and nutrition examination survey. Circulation 109(1):42–46. doi:10.1161/01.CIR.0000108926.04022.0C CrossRefPubMed

Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 62(5):707–714CrossRefPubMed

Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ (2012) Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307(12):1302–1309. doi:10.1001/jama.2012.366 CrossRefPubMed

deGoma EM, deGoma RL, Rader DJ (2008) Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51(23):2199–2211. doi:10.1016/j.jacc.2008.03.016 CrossRefPubMedPubMedCentral

Cuchel M, Rader DJ (2003) Genetics of increased HDL cholesterol levels: insights into the relationship between HDL metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 23(10):1710–1712. doi:10.1161/01.ATV.0000092947.15939.93 CrossRefPubMed

Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RP, Group PS (2006) An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 91(9):3382–3388. doi:10.1210/jc.2005-2322 CrossRef

Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365(24):2255–2267. doi:10.1056/NEJMoa1107579 CrossRef

Group HTC, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J (2014) Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371(3):203–212. doi:10.1056/NEJMoa1300955 CrossRef

10.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal OI (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367(22):2089–2099. doi:10.1056/NEJMoa1206797 CrossRefPubMed

11.

Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM (1996) The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 16(7):831–842CrossRefPubMed

12.

McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, Hahn BH (2006) Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54(8):2541–2549. doi:10.1002/art.21976 CrossRefPubMed

13.

Bernhoft RA (2012) Mercury toxicity and treatment: a review of the literature. J Environ Public Health 2012:460508. doi:10.1155/2012/460508 CrossRefPubMed

14.

Guallar E, Sanz-Gallardo MI, van’t Veer P, Bode P, Aro A, Gomez-Aracena J, Kark JD, Riemersma RA, Martin-Moreno JM, Kok FJ, Heavy M, Myocardial Infarction Study G (2002) Mercury, fish oils, and the risk of myocardial infarction. N Engl J Med 347(22):1747–1754. doi:10.1056/NEJMoa020157 CrossRef

15.

Boffetta P, Sallsten G, Garcia-Gomez M, Pompe-Kirn V, Zaridze D, Bulbulyan M, Caballero JD, Ceccarelli F, Kobal AB, Merler E (2001) Mortality from cardiovascular diseases and exposure to inorganic mercury. Occup Environ Med 58(7):461–466CrossRefPubMedPubMedCentral

16.

Choi B, Yeum KJ, Park SJ, Kim KN, Joo NS (2015) Elevated serum ferritin and mercury concentrations are associated with hypertension; analysis of the fourth and fifth Korea national health and nutrition examination survey (KNHANES IV-2, 3, 2008–2009 and V-1, 2010. Environ Toxicol 30(1):101–108. doi:10.1002/tox.21899 CrossRefPubMed

17.

Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, Chun C, Khang YH, Oh K (2014) Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol 43(1):69–77. doi:10.1093/ije/dyt228 CrossRefPubMedPubMedCentral

18.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart A, National Heart L, Blood I (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752. doi:10.1161/CIRCULATIONAHA.105.169404 CrossRefPubMed

19.

Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, Kim DY, Kwon HS, Kim SR, Lee CB, Oh SJ, Park CY, Yoo HJ (2007) Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract 75(1):72–80. doi:10.1016/j.diabres.2006.04.013 CrossRefPubMed

20.

Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41(9):1481–1494PubMed

21.

Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK 3rd, Roux-Lombard P, Burger D (2001) Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97(8):2381–2389CrossRefPubMed

22.

Serebruany VL, Gurbel PA, Murugesan SR, Lowry DR, Sturm E, Svetlov SI (1998) Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. Cardiology 90(2):127–130CrossRefPubMed

23.

Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G, Michiels C, Raes M, Bult H, Collen D, Van Veldhoven P, Ninio E, Holvoet P (2001) Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103(20):2495–2500CrossRefPubMed

24.

Ji J, Watts GF, Johnson AG, Chan DC, Ooi EM, Rye KA, Serone AP, Barrett PH (2006) High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J Clin Endocrinol Metab 91(3):973–979. doi:10.1210/jc.2005-1895 CrossRefPubMed

25.

Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371(25):2383–2393. doi:10.1056/NEJMoa1409065 CrossRefPubMedPubMedCentral

26.

Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364(2):127–135. doi:10.1056/NEJMoa1001689 CrossRefPubMedPubMedCentral

27.

Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96(6):2758–2767. doi:10.1172/JCI118345 CrossRefPubMedPubMedCentral

28.

Ehrenwald E, Chisolm GM, Fox PL (1994) Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 93(4):1493–1501. doi:10.1172/JCI117127 CrossRefPubMedPubMedCentral

29.

Lamb DJ, Leake DS (1994) Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein. FEBS Lett 338(2):122–126CrossRefPubMed

30.

Schwindt AR, Fournie JW, Landers DH, Schreck CB, Kent ML (2008) Mercury concentrations in salmonids from western US National Parks and relationships with age and macrophage aggregates. Environ Sci Technol 42(4):1365–1370CrossRefPubMed

31.

Gardner RM, Nyland JF, Evans SL, Wang SB, Doyle KM, Crainiceanu CM, Silbergeld EK (2009) Mercury induces an unopposed inflammatory response in human peripheral blood mononuclear cells in vitro. Environ Health Perspect 117(12):1932–1938. doi:10.1289/ehp.0900855 CrossRefPubMedPubMedCentral

32.

Kempuraj D, Asadi S, Zhang B, Manola A, Hogan J, Peterson E, Theoharides TC (2010) Mercury induces inflammatory mediator release from human mast cells. J Neuroinflammation 7:20. doi:10.1186/1742-2094-7-20 CrossRefPubMedPubMedCentral

33.

Gardner RM, Nyland JF, Silva IA, Ventura AM, de Souza JM, Silbergeld EK (2010) Mercury exposure, serum antinuclear/antinucleolar antibodies, and serum cytokine levels in mining populations in Amazonian Brazil: a cross-sectional study. Environ Res 110(4):345–354. doi:10.1016/j.envres.2010.02.001 CrossRefPubMedPubMedCentral

34.

Salonen JT, Seppanen K, Lakka TA, Salonen R, Kaplan GA (2000) Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis 148(2):265–273CrossRefPubMed

35.

Kim KN, Park SJ, Choi B, Joo NS (2015) Blood mercury and insulin resistance in nondiabetic Koreans (KNHANES 2008-2010). Yonsei Med J 56(4):944–950. doi:10.3349/ymj.2015.56.4.944 CrossRefPubMedPubMedCentral

36.

Kris-Etherton PM, Harris WS, Appel LJ, Association American Heart, Nutrition C (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106(21):2747–2757CrossRefPubMed

37.

Konig A, Bouzan C, Cohen JT, Connor WE, Kris-Etherton PM, Gray GM, Lawrence RS, Savitz DA, Teutsch SM (2005) A quantitative analysis of fish consumption and coronary heart disease mortality. Am J Prev Med 29(4):335–346. doi:10.1016/j.amepre.2005.07.001 CrossRefPubMed

38.

Zaribaf F, Falahi E, Barak F, Heidari M, Keshteli AH, Yazdannik A, Esmaillzadeh A (2014) Fish consumption is inversely associated with the metabolic syndrome. Eur J Clin Nutr 68(4):474–480. doi:10.1038/ejcn.2014.5 CrossRefPubMed

39.

Buscemi S, Nicolucci A, Lucisano G, Galvano F, Grosso G, Belmonte S, Sprini D, Migliaccio S, Cianferotti L, Brandi ML, Rini GB (2014) Habitual fish intake and clinically silent carotid atherosclerosis. Nutr J 13:2. doi:10.1186/1475-2891-13-2 CrossRefPubMedPubMedCentral

40.

Meltzer HM, Mundal HH, Alexander J, Bibow K, Ydersbond TA (1994) Does dietary arsenic and mercury affect cutaneous bleeding time and blood lipids in humans? Biol Trace Elem Res 46(1–2):135–153CrossRefPubMed

41.

Smith KM, Barraj LM, Kantor M, Sahyoun NR (2009) Relationship between fish intake, n-3 fatty acids, mercury and risk markers of CHD (National Health and Nutrition Examination Survey 1999-2002). Public Health Nutr 12(8):1261–1269. doi:10.1017/S1368980008003844 CrossRefPubMed

42.

Eom SY, Choi SH, Ahn SJ, Kim DK, Kim DW, Lim JA, Choi BS, Shin HJ, Yun SW, Yoon HJ, Kim YM, Hong YS, Yun YW, Sohn SJ, Kim H, Park KS, Pyo HS, Kim H, Oh SY, Kim J, Lee SA, Ha M, Kwon HJ, Park JD (2014) Reference levels of blood mercury and association with metabolic syndrome in Korean adults. Int Arch Occup Environ Health 87(5):501–513. doi:10.1007/s00420-013-0891-8 CrossRefPubMed

Title: Positive correlation of serum HDL cholesterol with blood mercury concentration in metabolic syndrome Korean men (analysis of KNANES 2008–2010, 2013)
Authors: S. J. Park
K. J. Yeum
B. Choi
Y. S. Kim
N. S. Joo
Publication date: 01-09-2016
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 9/2016
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-016-0459-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstracts

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2016

Evidence for decreased expression of APPL1 associated with reduced insulin and adiponectin receptors expression in PCOS patients

Premature ovarian insufficiency: the context of long-term effects

Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI

Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children

Exophthalmos (Graves’ orbitopathy) in an ancient sculpture

Testosterone supplementation and body composition: results from a meta-analysis of observational studies

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage